BIOMED-LUBLIN WYT.SUR.
Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents in Poland, rest of the European Union, and internationally. It operates through BCG and Traditional segments. The company offers OnkoBCG 50 and 100, which are oncological immunotherapy products used to treat superficial and non-invasive bladder tumors; GAMMA anty-D 5… Read more
Market Cap & Net Worth: BIOMED-LUBLIN WYT.SUR. (6NQ)
BIOMED-LUBLIN WYT.SUR. (F:6NQ) has a market capitalization of $65.96 Million (€64.26 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #22834 globally and #2484 in its home market, demonstrating a 7.97% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BIOMED-LUBLIN WYT.SUR.'s stock price €0.91 by its total outstanding shares 70770575 (70.77 Million).
BIOMED-LUBLIN WYT.SUR. Market Cap History: 2020 to 2026
BIOMED-LUBLIN WYT.SUR.'s market capitalization history from 2020 to 2026. Data shows change from $148.19 Million to $65.96 Million (-25.17% CAGR).
BIOMED-LUBLIN WYT.SUR. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BIOMED-LUBLIN WYT.SUR.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 6NQ by Market Capitalization
Companies near BIOMED-LUBLIN WYT.SUR. in the global market cap rankings as of March 19, 2026.
Key companies related to BIOMED-LUBLIN WYT.SUR. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
BIOMED-LUBLIN WYT.SUR. Historical Marketcap From 2020 to 2026
Between 2020 and today, BIOMED-LUBLIN WYT.SUR.'s market cap moved from $148.19 Million to $ 65.96 Million, with a yearly change of -25.17%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €65.96 Million | +26.64% |
| 2025 | €52.09 Million | -18.98% |
| 2024 | €64.29 Million | +1.84% |
| 2023 | €63.13 Million | -28.89% |
| 2022 | €88.77 Million | +24.06% |
| 2021 | €71.55 Million | -51.72% |
| 2020 | €148.19 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of BIOMED-LUBLIN WYT.SUR. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $65.96 Million USD |
| MoneyControl | $65.96 Million USD |
| MarketWatch | $65.96 Million USD |
| marketcap.company | $65.96 Million USD |
| Reuters | $65.96 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.